Eribulin Mesylate
RU011201I
Phase 3 small_molecule on_hold
Quick answer
Eribulin Mesylate for Breast Adenocarcinoma is a Phase 3 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Breast Adenocarcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- on_hold